Beta Drugs (BETA) Share Price Falls 9.03% as Small Cap Slips to Rs 1,726.70
- October 9, 2026
- Posted by: Kunal Singla
- Category: News
Beta Drugs Share Price moved lower in today’s trade, with Beta Drugs last traded at Rs 1,726.70 after a 9.03% decline from the previous close of Rs 1,898. The company’s market capitalisation stood at Rs 2,214.69 crore, placing it in the Small Cap category. According to Univest data, the price event is confirmed, but no company-specific catalyst is established. The move matters because the stock had opened above the previous close and then traded through a wide intraday range before settling near the lower end of that band. In today’s Beta Drugs Share Price update, the key question for investors is not only why the share price fell, but also how the company’s valuation, profitability and sector positioning compare with Healthcare peers. Univest data shows a sharp price action day, while the fundamental backdrop remains important for context.
Beta Drugs (BETA) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,726.7 |
| Previous Close | Rs 1,898 |
| Today's Move | -Rs 171.30 (-9.03%) |
| Open | Rs 1,910 |
| High | Rs 1,920 |
| Low | Rs 1,703.1 |
| Market Capitalisation | Rs 2,214.69 crore |
| Market Cap Category | Small Cap |
Beta Drugs Share Price Today reflects a clear intraday decline. The stock opened at Rs 1,910, touched a high of Rs 1,920 and a low of Rs 1,703.10, before last trading at Rs 1,726.70. That leaves it Rs 171.30 below the previous close of Rs 1,898, a move of 9.03% on the day. The market capitalisation of Rs 2,214.69 crore keeps Beta Drugs in the Small Cap category, which is relevant when reading today’s move in context. The day’s range shows that Beta Drugs Share Price moved from an early level above the previous close to a much weaker intraday level. For readers tracking Beta Drugs Share Price Live, the important fact is the combination of a lower last traded price, a wide range and a negative day change. The next layer is the company’s Fundamental Analysis.
Beta Drugs (BETA) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 2,214.69 crore |
| P/E Ratio | 50.88x |
| P/B Ratio | 8.05x |
| ROE | 23.95% |
| ROCE | 25.23% |
| EPS | Rs 37.3 |
| Book Value Per Share | Rs 235.8 |
| Dividend Yield | 0% |
Beta Drugs (BETA) fundamental metrics show P/E 50.88x, P/B 8.05x, ROE 23.95%, ROCE 25.23%. These figures provide context only and are not a buy or sell signal.
Beta Drugs has a market capitalisation of Rs 2,214.69 crore and falls in the Small Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 50.88x, P/B at 8.05x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 23.95% and ROCE of 25.23%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 37.3, book value per share of Rs 235.8, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.28x, median ROE of 11.61%, median ROCE of 13.46%. Taken together, they outline the fundamentals rather than a view on the stock.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 50.88x |
| Benchmark Median P/E | 31.28x |
| Benchmark Average P/E | 47.09x |
| Benchmark P/E Range | 3.56x to 678.22x |
| Company P/B Ratio | 8.05x |
| Benchmark Median P/B | 2.85x |
| Benchmark Average P/B | 4.25x |
| Company ROE | 23.95% |
| Benchmark Median ROE | 11.61% |
| Benchmark Average ROE | 10.59% |
| Company ROCE | 25.23% |
| Benchmark Median ROCE | 13.46% |
| Benchmark Average ROCE | 13.36% |
| Company Market Capitalisation | Rs 2,214.69 crore |
| Benchmark Median Market Cap | Rs 821.44 crore |
| Benchmark Average Market Cap | Rs 14,054.13 crore |
Beta Drugs (BETA) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Beta Drugs (BETA) has a P/E ratio of 50.88x, which is above the benchmark median of 31.28x, a difference of +62.66%. On its own, the P/E gap is a valuation reference point, not a trading call.
Beta Drugs (BETA) has a ROE of 23.95%, which is above the benchmark median of 11.61%, a difference of +106.29%. Beta Drugs (BETA) has a ROCE of 25.23%, which is above the benchmark median of 13.46%, a difference of +87.44%.
Track stocks among today's decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,27,861.41 | 34.76 | 4.86 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,54,318.9 | 85.21 | 14.11 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,79,153.26 | 81.53 | 19.81 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,15,111.94 | 24.65 | 4.13 | 19.69 | 21.39 |
| Laurus Labs | LAURUSLABS | 1,11,034.16 | 98.83 | 19.16 | 18.31 | 18.2 |
Beta Drugs (BETA) has a P/E ratio of 50.88x compared with the displayed peer median of 81.53x. This peer read is a relative benchmark rather than a trading signal. Its ROE of 23.95% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 25.23% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Beta Drugs (BETA) has a market capitalisation of Rs 2,214.69 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Beta Drugs
- Beta Drugs Share Price fell 9.03% in today’s trade, which makes the intraday price action the first focus for market watchers.
- The stock last traded at Rs 1,726.70 after moving between Rs 1,703.10 and Rs 1,920, showing a wide day range.
- Beta Drugs Share Price carries a P/E of 50.88 and a P/B of 8.05, so valuation remains an important part of stock analysis.
- ROE of 23.95% and ROCE of 25.23% show strong return metrics in the latest Univest data.
- In Healthcare and Pharmaceuticals & Drugs, Beta Drugs Share Price can be compared with peers that trade on very different valuation and scale levels.
About Beta Drugs
Beta Drugs operates in the Healthcare sector within the Pharmaceuticals & Drugs industry. Beta Drugs Share Price is therefore tied to a business linked to medicine and pharmaceutical activity rather than a broad industrial or financial model. The company is treated as a Small Cap in today’s market context, with market capitalisation of Rs 2,214.69 crore. In the latest Univest figures, the company’s profile is defined more by valuation and return ratios than by a broad operating segment breakdown. For investors reading Beta Drugs Stock News, the core business context is that the company belongs to the pharmaceutical value chain, and its share price is now being assessed alongside sector peers and industry benchmarks.
Track Beta Drugs Share Price on Univest
Use Beta Drugs (BETA) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.
Readers can track Beta Drugs Share Price on Univest for live price movement, fundamental ratios, 52-week levels and market insights in one place. Beta Drugs Share Price Today can be followed alongside sector context, peer comparison and stock analysis. Univest data helps place each change in valuation, returns and market cap into a clearer research view.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why did Beta Drugs Share Price fall today?
Ans. Beta Drugs Share Price fell 9.03% and last traded at Rs 1,726.70, but the data only confirms the price event. According to Univest data, no company-specific catalyst is established. The previous close was Rs 1,898.
What is Beta Drugs Share Price Today?
Ans. Beta Drugs Share Price Today was Rs 1,726.70, down Rs 171.30 from the previous close of Rs 1,898. The stock opened at Rs 1,910 and touched an intraday high of Rs 1,920.
How much did Beta Drugs Share Price decline?
Ans. Beta Drugs Share Price declined by 9.03% in the latest session. The fall took the stock from the previous close of Rs 1,898 to a last traded price of Rs 1,726.70.
What is Beta Drugs market cap?
Ans. Beta Drugs has a market capitalisation of Rs 2,214.69 crore, which places it in the Small Cap category. That size is useful context when comparing Beta Drugs Share Price with larger Healthcare peers.
Is Beta Drugs valued cheaply or richly?
Ans. Beta Drugs Share Price trades on a P/E of 50.88 and P/B of 8.05, both above the same-industry benchmark median. Those numbers point to a richer valuation than the benchmark centre.
What do ROE and ROCE show for Beta Drugs?
Ans. Beta Drugs reports ROE of 23.95% and ROCE of 25.23%. Those figures are above the same-industry benchmark medians, which gives Beta Drugs Share Price stronger return context than many peers.
What is the EPS and book value for Beta Drugs?
Ans. Beta Drugs reports EPS of Rs 37.30 and book value of Rs 235.80 per share. These figures help explain the accounting and earnings base behind Beta Drugs Share Price in today’s market view.
Does Beta Drugs pay a dividend?
Ans. Beta Drugs shows a dividend yield of 0% in the latest Univest figures. For Beta Drugs Share Price, that means the current analysis is driven more by valuation and returns than by payout yield.
How does Beta Drugs compare with Healthcare peers?
Ans. Beta Drugs Share Price sits far below large peers such as Sun Pharma in market cap, while its P/E of 50.88 is above Zydus Lifesciences and below Divi’s Laboratories and Torrent Pharmaceuticals.
